Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. - Wikidata - awgldk - TriplyDB

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q34860750

about

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects Targeting BET bromodomains for cancer treatment dbSUPER: a database of super-enhancers in mouse and human genome Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc Role of MYC in B Cell Lymphomagenesis.BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Bromodomain and hedgehog pathway targets in small cell lung cancer.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.Relapsed/refractory Burkitt lymphoma and HIV infection.Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies

P2860

Q27304386-CC9E4F5D-6AB3-4E0B-8A50-4D9B9CAE8257 Q28066765-D4A9A05A-5D5D-460E-8429-C617FB631959 Q28263519-B39F778D-99F2-4717-9F35-569A08C2CBD0 Q28603137-3AA7E4B6-D4FF-4A4E-8C21-21F654F32F14 Q28647939-FDFA3686-9B4D-47CB-94BF-BB658416D10E Q33608499-62114C5A-8060-4942-B9AD-BCBC9B88BAEA Q35574955-8F1F90BA-6FFB-4CCA-8386-3F8F4362A973 Q35767389-3E1A22F1-BF31-428C-965B-D0C26AE7D7D0 Q36274292-3C88356C-2CC1-4044-8E30-6816F350599E Q36535682-A8E112F4-A1AA-4CB3-8027-DE80DF43F44A Q36725307-65C7F25D-1EB7-403A-87BE-AD36E3DCB497 Q36764845-DFFCAE28-0D5C-45B9-9DF8-DB3746684C29 Q36918007-F018B71F-FAD3-4EDF-91FA-305E7FF98202 Q37234543-49C3347E-6404-46B5-A3DC-5C883CFC10A3 Q37493633-AFCC771A-95CF-4E11-A1FF-C7F96AD87E96 Q37688355-6B56E201-820A-4133-9964-C8D9D094A36F Q37733990-FEFDD043-D198-4F9B-8EF6-BCF3EBFE7C53 Q38409231-9D3B4194-1D6A-476A-90AD-3BD14BFF5AF3 Q38568358-B63419BD-641D-438D-958D-048B5363F4EE Q38646971-0BA26FBA-EA37-46AF-9835-78FAE9E4376D Q38656983-34973CB8-A271-435E-9DEB-E6A79B7A4407 Q38779981-9EFE70FE-F412-4DF3-92B3-91C2482C0A3C Q39001598-B9EEB8C9-5394-4B6A-B944-1AECAEEA57D6 Q39024306-F1B216B4-3B8E-4DF5-968E-95B257005ACA Q39207675-8108E14A-3759-4E7E-8CA1-ED2F5DB52091 Q39520264-12874F5C-F74A-4A6A-8D3A-BEFE29C25350 Q39924163-F33C35D8-42E3-4CD0-9D45-9EC443EDF780 Q40067410-135A9B59-01E0-44F3-95B4-9529CC7C1E93 Q42701804-2B66EE48-7AE5-474A-8297-520FD0D51220 Q47562321-89FCB913-3981-41EF-84D7-61C7B6BC59D9 Q54982413-0364BA39-3A6A-4A12-90E5-86F7419E5D73 Q55281964-D937D62F-7EDF-4B0D-84AF-7D6F89D16450 Q55713061-527FD080-512A-462E-B6F9-C798F670F433 Q57299887-ABBB58BA-349A-480C-8163-0D06824DCBF2 Q57493686-96A33AC7-6FB3-4A4A-ACB4-3951BB43F181

P2860

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q34860750

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@ast

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@en

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@nl

type

label

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@ast

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@en

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@nl

prefLabel

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@ast

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@en

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma.

@nl

P1433

Q34860750-B2FD2400-88C2-42E3-A39C-9B601B3C960D

P1476

Q34860750-EC9E70B8-D864-4F53-B8E9-D82A004AE4AE

P2093

Q34860750-25301CDE-9999-498C-8478-BFE2CBEDEBA2

Q34860750-436570E8-9A96-4249-8BB5-9B1154CE4C76

Q34860750-46D7B55D-8465-43D9-9517-2B4564AF1130

Q34860750-A1CAD8BF-4297-4E86-A8F5-E5C7C7139A45

Q34860750-C2BB2C31-C926-4106-B2ED-3F5FDA91AFB2

Q34860750-FF60F45B-A4E1-4BA5-8A3F-80D7D5B69670

P2860

Q34860750-00CE72C5-2BD4-455D-88B6-9EA49348BF52

Q34860750-0708E1CD-8ED8-4D87-B6D0-416ABEFCA358

Q34860750-0B2217A0-044C-447F-A8B2-2C5A227BA128

Q34860750-11992F2D-DBD6-4726-899D-AA4AAA49D4F8

Q34860750-140F2331-9AB0-4396-8968-54F023D67EE0

Q34860750-2FBF6A2A-FAFF-4358-837D-E2342FA62899

Q34860750-38710584-31E6-4A48-ADF1-8BDD3C504BF0

Q34860750-3AEA671B-F970-4E08-8272-AAD80168EFDA

Q34860750-3B714804-384F-4024-A0BA-78E8A1A0DE84

Q34860750-3DA41D4A-43BA-4380-984D-4CBC53658B42

P304

Q34860750-C2B80CAE-AAF7-4A11-80AB-EEF50B1C0E78

P31

Q34860750-A08275D1-7632-47FE-8E15-A36A7348A906

P356

Q34860750-CB5A5728-47A3-4983-88C7-526BFF86ADFF

P407

Q34860750-F198F487-E461-4AFB-B2D4-799D486F6805

P433

Q34860750-6319689F-2326-4C4E-AAB3-0933A5881796

P478

Q34860750-D77CEDE5-3549-4F72-995E-049AC1F9F77C

P50

Q34860750-D9A3A314-6C00-4FB4-A202-F17C97EAB542

P577

Q34860750-968F965C-41E7-4D5D-9D6B-2A31DB41886F

P698

Q34860750-EAE3977E-94B1-4954-B9D4-EAEDAD787772

P932

Q34860750-E57EAFB1-3204-4F10-9E22-BB53436A13A2

P356

1078-0432.CCR-13-3346

P1433

Clinical Cancer Research

P1476

Inhibition of bromodomain prot ...... diffuse large B-cell lymphoma

@en

P2093

Dale L Greiner

http://www.w3.org/2001/XMLSchema#string

Hong Zhang

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Leonard D Shultz

http://www.w3.org/2001/XMLSchema#string

Rachel M Gerstein

http://www.w3.org/2001/XMLSchema#string

Sally E Trabucco

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

P304

113-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-3346

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25009295

http://www.w3.org/2001/XMLSchema#string

P932

4286476

http://www.w3.org/2001/XMLSchema#string